Louvain-La-Neuve, Belgium, 20 October, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of dosimetry solutions, is pleased to announce it has received approval from Varian, a Siemens Healthineers Company, for compatibility for its dosimetry solutions, MatriXX Resolution™ and  myQA® SRS, with Varian’s radiotherapy and adaptive therapy solutions, Halcyon® and Ethos™.

Through the use of IBA Dosimetry’s Gantry Sensor+ feature, IBA’s MatriXX Resolution™, the high-resolution IMRT/VMAT quality assurance (QA) detector, and myQA® SRS, the film-class resolution stereotactic detector, are now fully compatible with Varian Halcyon® and Ethos™. The Gantry Sensor+, when combined with the Varian Halcyon® and Ethos™, provides real-time measurements for precise angular corrections.

myQA® SRS is the first stereotactic detector with a large active detector area (12 x 14 cm²) that provides film-class resolution of 0.4 mm with 105,000 pixels. MatriXX Resolution™, the latest member of the MatriXX detector family, is a completely wireless IMRT/VMAT detector array with a 6.5 mm resolution and more than 1,500 ionization chambers. Both detector arrays feature the highest resolution available in the market for their specific field of use and provide users with the capability to perform pre-treatment Patient QA in native plan geometry.

Jean-Marc Bothy, President of IBA Dosimetry, says: “IBA Dosimetry has become the first provider with a QA solution to qualify for Varian’s extensive interoperability program. This compatibility will allow an even larger radiotherapy community to benefit from our Patient QA solutions whilst ensuring patient plan verification for Varian Halcyon® and Ethos™ users in native geometries, as suggested by multiple international protocols.” 




About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the areas of industrial sterilization, radiopharmaceuticals, and dosimetry. Based in Louvain-la-Neuve, Belgium, the company employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest verified social and environmental performance standards.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com